Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.

Modvig S, Madsen HO, Siitonen SM, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Thörn I, Matuzeviciene R, Stoskus M, Marincevic M, Fogelstrand L, Lilleorg A, Toft N, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Schmiegelow K, Marquart HV.

Leukemia. 2018 Dec 14. doi: 10.1038/s41375-018-0307-6. [Epub ahead of print]

PMID:
30552401
2.

CD99 expression is strongly associated with clinical outcome in children with B-cell precursor acute lymphoblastic leukaemia.

Chen D, Camponeschi A, Wu Q, Gerasimcik N, Li H, Shen X, Tan Y, Sjögren H, Nordlund J, Lönnerholm G, Abrahamsson J, Fogelstrand L, Mårtensson IL.

Br J Haematol. 2019 Feb;184(3):418-423. doi: 10.1111/bjh.15683. Epub 2018 Nov 28.

PMID:
30484860
3.

The endothelin receptor type A is a downstream target of Hoxa9 and Meis1 in acute myeloid leukemia.

Arabanian LS, Johansson P, Staffas A, Nilsson T, Rouhi A, Fogelstrand L, Palmqvist L.

Leuk Res. 2018 Dec;75:61-68. doi: 10.1016/j.leukres.2018.10.005. Epub 2018 Oct 13.

PMID:
30384975
4.

Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.

Delsing Malmberg E, Rehammar A, Pereira MB, Abrahamsson J, Samuelsson T, Ståhlman S, Asp J, Tierens A, Palmqvist L, Kristiansson E, Fogelstrand L.

J Mol Diagn. 2019 Jan;21(1):149-162. doi: 10.1016/j.jmoldx.2018.08.004. Epub 2018 Sep 29.

PMID:
30273780
5.

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.

Delsing Malmberg E, Johansson Alm S, Nicklasson M, Lazarevic V, Ståhlman S, Samuelsson T, Lenhoff S, Asp J, Ehinger M, Palmqvist L, Brune M, Fogelstrand L.

Leuk Lymphoma. 2018 Aug 2:1-9. doi: 10.1080/10428194.2018.1485910. [Epub ahead of print]

PMID:
30068244
6.

Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia.

Schneider E, Staffas A, Röhner L, Malmberg ED, Ashouri A, Krowiorz K, Pochert N, Miller C, Wei SY, Arabanian L, Buske C, Döhner H, Bullinger L, Fogelstrand L, Heuser M, Döhner K, Xiang P, Ruschmann J, Petriv OI, Heravi-Moussavi A, Hansen CL, Hirst M, Humphries RK, Rouhi A, Palmqvist L, Kuchenbauer F.

Haematologica. 2018 Feb;103(2):246-255. doi: 10.3324/haematol.2017.177485. Epub 2017 Dec 7.

7.

CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemia.

Chen D, Gerasimčik N, Camponeschi A, Tan Y, Wu Q, Brynjolfsson S, Zheng J, Abrahamsson J, Nordlund J, Lönnerholm G, Fogelstrand L, Mårtensson IL.

Blood Cancer J. 2017 Jun 23;7(6):e575. doi: 10.1038/bcj.2017.55. No abstract available.

8.

Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.

Alm SJ, Engvall C, Asp J, Palmqvist L, Abrahamsson J, Fogelstrand L.

Int J Lab Hematol. 2017 Apr;39(2):121-128. doi: 10.1111/ijlh.12593. Epub 2016 Dec 22.

PMID:
28004528
9.

Early hematopoiesis in multiple sclerosis patients.

Jons D, Kneider M, Fogelstrand L, Jeppsson A, Jacobsson S, Andersen O.

J Neuroimmunol. 2016 Oct 15;299:158-163. doi: 10.1016/j.jneuroim.2016.09.004. Epub 2016 Sep 13.

PMID:
27725115
10.

MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.

Schneider E, Staffas A, Röhner L, Krowiorz K, Heuser M, Döhner K, Bullinger L, Döhner H, Fogelstrand L, Rouhi A, Kuchenbauer F, Palmqvist L.

Exp Hematol. 2016 Dec;44(12):1166-1171. doi: 10.1016/j.exphem.2016.08.012. Epub 2016 Sep 13.

PMID:
27619068
11.

Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.

Staffas A, Arabanian LS, Wei SY, Jansson A, Ståhlman S, Johansson P, Fogelstrand L, Cammenga J, Kuchenbauer F, Palmqvist L.

Oncogene. 2017 Mar;36(11):1516-1524. doi: 10.1038/onc.2016.318. Epub 2016 Sep 12.

PMID:
27617578
12.

The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia.

Chen D, Zheng J, Gerasimcik N, Lagerstedt K, Sjögren H, Abrahamsson J, Fogelstrand L, Mårtensson IL.

PLoS One. 2016 Sep 9;11(9):e0162638. doi: 10.1371/journal.pone.0162638. eCollection 2016.

13.

Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.

Malmberg EB, Ståhlman S, Rehammar A, Samuelsson T, Alm SJ, Kristiansson E, Abrahamsson J, Garelius H, Pettersson L, Ehinger M, Palmqvist L, Fogelstrand L.

Eur J Haematol. 2017 Jan;98(1):26-37. doi: 10.1111/ejh.12780. Epub 2016 Jun 8.

PMID:
27197529
14.

Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.

Tierens A, Bjørklund E, Siitonen S, Marquart HV, Wulff-Juergensen G, Pelliniemi TT, Forestier E, Hasle H, Jahnukainen K, Lausen B, Jonsson OG, Palle J, Zeller B, Fogelstrand L, Abrahamsson J.

Br J Haematol. 2016 Aug;174(4):600-9. doi: 10.1111/bjh.14093. Epub 2016 Apr 13.

PMID:
27072379
15.

PAX5-ESRRB is a recurrent fusion gene in B-cell precursor pediatric acute lymphoblastic leukemia.

Marincevic-Zuniga Y, Zachariadis V, Cavelier L, Castor A, Barbany G, Forestier E, Fogelstrand L, Heyman M, Abrahamsson J, Lönnerholm G, Nordgren A, Syvänen AC, Nordlund J.

Haematologica. 2016 Jan;101(1):e20-3. doi: 10.3324/haematol.2015.132332. Epub 2015 Oct 22. No abstract available.

16.

The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.

Paulsson K, Lilljebjörn H, Biloglav A, Olsson L, Rissler M, Castor A, Barbany G, Fogelstrand L, Nordgren A, Sjögren H, Fioretos T, Johansson B.

Nat Genet. 2015 Jun;47(6):672-6. doi: 10.1038/ng.3301. Epub 2015 May 11.

PMID:
25961940
17.

MCPH1 maintains long-term epigenetic silencing of ANGPT2 in chronic lymphocytic leukemia.

Kopparapu PK, Miranda C, Fogelstrand L, Mishra K, Andersson PO, Kanduri C, Kanduri M.

FEBS J. 2015 May;282(10):1939-52. doi: 10.1111/febs.13245. Epub 2015 Mar 9.

18.

Exploring the heterogeneity of the hematopoietic stem and progenitor cell pool in cord blood: simultaneous staining for side population, aldehyde dehydrogenase activity, and CD34 expression.

Frändberg S, Boreström C, Li S, Fogelstrand L, Palmqvist L.

Transfusion. 2015 Jun;55(6):1283-9. doi: 10.1111/trf.13013. Epub 2015 Feb 3.

PMID:
25647229
19.

p27(KIP1) and PTEN cooperate in myeloproliferative neoplasm tumor suppression in mice.

Shao J, Li S, Palmqvist L, Fogelstrand L, Wei SY, Busayavalasa K, Liu K, Liu VM.

Exp Hematol Oncol. 2016 Jun 30;5:17. doi: 10.1186/s40164-016-0047-0. eCollection 2015.

20.

α7 Nicotinic acetylcholine receptor is expressed in human atherosclerosis and inhibits disease in mice--brief report.

Johansson ME, Ulleryd MA, Bernardi A, Lundberg AM, Andersson A, Folkersen L, Fogelstrand L, Islander U, Yan ZQ, Hansson GK.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2632-6. doi: 10.1161/ATVBAHA.114.303892. Epub 2014 Oct 16.

PMID:
25324572
21.

High functional CD70 expression on α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia.

Junevik K, Werlenius O, Fogelstrand L, Karlsson-Parra A, Andersson PO.

Scand J Immunol. 2014 Jun;79(6):415-22. doi: 10.1111/sji.12172.

22.

Reduced IgM levels and elevated IgG levels against oxidized low-density lipoproteins in HIV-1 infection.

Yilmaz A, Jennbacken K, Fogelstrand L.

BMC Infect Dis. 2014 Mar 17;14:143. doi: 10.1186/1471-2334-14-143.

23.

Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-ALL treated according to the NOPHO ALL-1992 and ALL-2000 protocols.

Fogelstrand L, Staffas A, Wasslavik C, Sjögren H, Söderhäll S, Frost BM, Forestier E, Degerman S, Behrendtz M, Heldrup J, Karrman K, Johansson B, Heyman M, Abrahamsson J, Palmqvist L.

Pediatr Blood Cancer. 2014 Mar;61(3):424-30. doi: 10.1002/pbc.24803. Epub 2013 Oct 8.

PMID:
24424791
24.

Glucose impairs B-1 cell function in diabetes.

Jennbacken K, Ståhlman S, Grahnemo L, Wiklund O, Fogelstrand L.

Clin Exp Immunol. 2013 Oct;174(1):129-38. doi: 10.1111/cei.12148.

25.

Rip2 deficiency leads to increased atherosclerosis despite decreased inflammation.

Levin MC, Jirholt P, Wramstedt A, Johansson ME, Lundberg AM, Trajkovska MG, Ståhlman M, Fogelstrand P, Brisslert M, Fogelstrand L, Yan ZQ, Hansson GK, Björkbacka H, Olofsson SO, Borén J.

Circ Res. 2011 Nov 11;109(11):1210-8. doi: 10.1161/CIRCRESAHA.111.246702. Epub 2011 Sep 29.

PMID:
21959219
26.

LDL-associated apolipoprotein J and lysozyme are associated with atherogenic properties of LDL found in type 2 diabetes and the metabolic syndrome.

Pettersson C, Karlsson H, Ståhlman M, Larsson T, Fagerberg B, Lindahl M, Wiklund O, Borén J, Fogelstrand L.

J Intern Med. 2011 Mar;269(3):306-21. doi: 10.1111/j.1365-2796.2010.02292.x.

27.

Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses.

Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, Vanhaesebroeck B, Witztum JL, Puri KD, Gold MR.

J Immunol. 2009 Nov 1;183(9):5673-84. doi: 10.4049/jimmunol.0900432.

28.

Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans.

Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, Shaw PX, Choi J, Perkmann T, Bäckhed F, Miller YI, Hörkkö S, Corr M, Witztum JL, Binder CJ.

J Clin Invest. 2009 May;119(5):1335-49. doi: 10.1172/JCI36800. Epub 2009 Apr 13.

29.

Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages.

Håversen L, Danielsson KN, Fogelstrand L, Wiklund O.

Atherosclerosis. 2009 Feb;202(2):382-93. doi: 10.1016/j.atherosclerosis.2008.05.033. Epub 2008 May 28.

PMID:
18599066
30.

Oxidation-specific epitopes are important targets of innate immunity.

Chou MY, Hartvigsen K, Hansen LF, Fogelstrand L, Shaw PX, Boullier A, Binder CJ, Witztum JL.

J Intern Med. 2008 May;263(5):479-88. doi: 10.1111/j.1365-2796.2008.01968.x. Review.

31.

Natural antibodies in murine atherosclerosis.

Binder CJ, Chou MY, Fogelstrand L, Hartvigsen K, Shaw PX, Boullier A, Witztum JL.

Curr Drug Targets. 2008 Mar;9(3):190-5. Review.

PMID:
18336236
32.

Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia.

Pettersson C, Fogelstrand L, Rosengren B, Ståhlman S, Hurt-Camejo E, Fagerberg B, Wiklund O.

J Intern Med. 2008 Aug;264(2):155-65. doi: 10.1111/j.1365-2796.2008.01932.x. Epub 2008 Feb 20.

33.

Circulating soluble CD44 is higher among women than men and is not associated with cardiovascular risk factors or subclinical atherosclerosis.

Sjöberg S, Fogelstrand L, Hulthe J, Fagerberg B, Krettek A.

Metabolism. 2005 Feb;54(2):139-41.

PMID:
15690305
34.

Monocytic expression of CD14 and CD18, circulating adhesion molecules and inflammatory markers in women with diabetes mellitus and impaired glucose tolerance.

Fogelstrand L, Hulthe J, Hultén LM, Wiklund O, Fagerberg B.

Diabetologia. 2004 Nov;47(11):1948-52. Epub 2004 Nov 19.

PMID:
15558232

Supplemental Content

Loading ...
Support Center